Daraxonrasib for Pancreatic Cancer

The FDA approved daraxonrasib, a new oral targeted therapy for stage 4 pancreatic cancer, which has shown to nearly double survival rates compared to chemotherapy. The drug blocks multiple RAS protein types, a mutation present in 90% of pancreatic cancers, and is already offered early to patients at Mass General Brigham Cancer Institute.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.